Total patients | Non-antiplatelet HAS-BLED score | p | ||
---|---|---|---|---|
0–2 | 3 or more | |||
All CAD, n (%) | 408 | 353 | 55 | |
No antiplatelet | 222 (54.4%) | 196 (55.5%) | 26 (47.3%) | 0.253 |
Single antiplatelet | 153 (37.5%) | 128 (36.3%) | 25 (45.5%) | 0.190 |
Dual antiplatelets | 33 (8.1%) | 29 (8.2%) | 4 (7.3%) | 1.000 |
DES < 1 year, n (%) | 27 | 23 | 4 | |
No antiplatelet | 3 (11.1%) | 3 (13.0%) | 0 (0.0%) | 1.000 |
Single antiplatelet | 7 (25.9%) | 6 (26.1%) | 1 (25.0%) | 1.000 |
Dual antiplatelets | 17 (63.0%) | 14 (60.9%) | 3 (75.0%) | 1.000 |
DES > 1 year or BMS for any duration, n (%) | 125 | 108 | 17 | |
No antiplatelet | 41 (32.8%) | 35 (32.4%) | 6 (35.3%) | 0.814 |
Single antiplatelet | 73 (58.4%) | 63 (58.3%) | 10 (58.8%) | 0.970 |
Dual antiplatelets | 11 (8.8%) | 10 (9.3%) | 1 (5.9%) | 1.000 |
History of ACS within 1 year, n (%) | 42 | 33 | 9 | |
No antiplatelet | 21 (50.0%) | 17 (51.5%) | 4 (44.4%) | 1.000 |
Single antiplatelet | 12 (28.6%) | 9 (27.3%) | 3 (33.3%) | 0.699 |
Dual antiplatelets | 9 (21.4%) | 7 (21.2%) | 2 (22.2%) | 1.000 |
CAD without prior ACS or PCI, n (%) | 386 | 332 | 54 | |
No antiplatelet | 189 (56.9%) | 26 (48.1%) | 0.102 | |
Single antiplatelet | 115 (34.6%) | 25 (46.3%) | 0.053 | |
Dual antiplatelets | 28 (8.4%) | 3 (5.6%) | 1.000 |